|
US2020188371A1
|
|
Methods for the treatment of dyskinesia in cerebral palsy
|
|
SG11201908477QA
|
|
Analogs of deutetrabenazine, their preparation and use
|
|
WO2018106850A1
|
|
Deuterated aminopyridine compounds
|
|
US2018079742A1
|
|
Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
|
|
US2018064726A1
|
|
Deuterium-Substituted Oxazepin Compounds
|
|
EP3400212A1
|
|
Tetrahydrocarbazole inhibitors of sirt1 receptors
|
|
EP3400211A1
|
|
Azetidine modulators of the sphingosine 1-phosphate receptor
|
|
WO2017065899A1
|
|
Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders
|
|
IL246768D0
|
|
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
HK1216635A1
|
|
Substituted phenethylamines with serotoninergic and or norepinephrinergic activity
|
|
AU2016246398A1
|
|
Deuterium-substituted oxadiazoles
|
|
US2016222008A1
|
|
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
KR20170122820A
|
|
Treatment of abnormal involuntary movement disorders
|
|
US2018036260A1
|
|
Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
|
|
WO2016109361A2
|
|
3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
|
|
EP3240539A1
|
|
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2016109359A1
|
|
Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
|
|
WO2016109360A1
|
|
Dihydroquinazoline inhibitors of viral terminase
|
|
WO2015171345A1
|
|
N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
|
|
US2016346200A1
|
|
Pharmaceutical formulations
|
